The New Wave in Diagnosis and Treatment
of pelvic conditions
a digital platform for earlier diagnosis of endometriosis
This project has been funded by The European Union, under the grant agreement n° 101099775.
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union and cannot be held responsible for them.
ENDOMETRIOSIS
Affects 1 in 10 individuals who menstruate
Endometriosis is caused by tissue, similar to that which lines the uterus, growing outside the uterus.
Symptoms are highly individual
Patients with endometriosis present with severe but non-specific symptoms, most notably chronic pelvic pain (70% of patients live with unresolved pain) and infertility (half of endometriosis patients suffer from fertility issues, and up to half of women with unexplained infertility are subsequently found to have endometriosis).
Long Diagnostic Delay
Endometriosis is often misdiagnosed (up to 75% of cases) or remains undiagnosed for a long period of time (4-11 years from symptom onset to diagnosis).
$78–119 billion annually
$78–119 billion annually
OnaWave Medical
Our Mission & Vision
Our Mission
Our Vision
Our Objectives
Making Diagnosis Earlier and Easier
Novel Digital Biomarker
Novel Digital Biomarker with potential to diagnose, monitor and treat pelvic conditions.
Earlier & Easier Diagnosis
Non-invasive medical device perscrbed by the physician and worn at home
Reduce The Cost of Diagnosis
Provide answers to reduce the time to diagnosis and mis-diagnosis
Better Patient Outcomes
Enable personalised care and potential to monitor the effectiveness of treatments
Potential for new treatment approach
Harnessing the body's own biological activity and technology in the development of new therapeutic approaches
OUR SOLUTION
OUR PARTNERS
